• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Immunol . Type I interferon signaling deficiency results in dysregulated innate immune responses to SARS-CoV-2 in mice

tetano

Editor, Senior Moderator
Eur J Immunol


. 2022 Sep 15.
doi: 10.1002/eji.202249913. Online ahead of print.
Type I interferon signaling deficiency results in dysregulated innate immune responses to SARS-CoV-2 in mice


Patricia P Ogger[SUP] 1 [/SUP], Minerva Garcia Martín[SUP] 1 [/SUP], Christina Michalaki[SUP] 1 [/SUP], Jie Zhou[SUP] 2 [/SUP], Jonathan C Brown[SUP] 2 [/SUP], Yue Du[SUP] 3 [/SUP], Kamran M Miah[SUP] 3 [/SUP], Omar Habib[SUP] 3 [/SUP], Stephen C Hyde[SUP] 3 [/SUP], Deborah R Gill[SUP] 3 [/SUP], Wendy S Barclay[SUP] 2 [/SUP], Cecilia Johansson[SUP] 1 [/SUP]



Affiliations

Abstract

SARS-CoV-2 is a newly emerged coronavirus, causing the global pandemic of respiratory coronavirus disease (COVID-19). The type I interferon (IFN) pathway is of particular importance for anti-viral defence and recent studies identified that type I IFNs drive early inflammatory responses to SARS-CoV-2. Here, we use a mouse model of SARS-CoV-2 infection, facilitating viral entry by intranasal recombinant Adeno-Associated Virus (rAAV) transduction of hACE2 in wildtype (WT) and type I IFN-signalling-deficient (Ifnar1[SUP]-/-[/SUP] ) mice, to study type I IFN signalling deficiency and innate immune responses during SARS-CoV-2 infection. Our data show that type I IFN signaling is essential for inducing anti-viral effector responses to SARS-CoV-2, control of virus replication and to prevent enhanced disease. Furthermore, hACE2-Ifnar1[SUP]-/-[/SUP] mice had increased gene expression of the chemokine Cxcl1 and airway infiltration of neutrophils as well as a reduced and delayed production of monocyte-recruiting chemokine CCL2. hACE2-Ifnar1[SUP]-/-[/SUP] mice showed altered recruitment of inflammatory myeloid cells to the lung upon SARS-CoV-2 infection, with a shift from Ly6C[SUP]+[/SUP] to Ly6C[SUP]-[/SUP] expressing cells. Together, our findings suggest that type I IFN deficiency results in a dysregulated innate immune response to SARS-CoV-2 infection. This article is protected by copyright. All rights reserved.

Keywords: In vivo; Innate Immune Response/ type I IFN; SARS-CoV-2/ myeloid cells.
 
Back
Top Bottom